Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


AVONTEC broadens US patent protection for its lead candidate AVT-01 decoy ODN

Martinsried/Munich, July 07, 2009. AVONTEC GmbH, a privately held biopharmaceutical company dedicated to the development of novel therapies for chronic inflammatory diseases, today announced that the US Patent and Trademark office has granted a further patent on the company’s lead development candidate AVT-01 decoy ODN.

Patent no. US 7 485 628 relates in general to oligonucleotide based inhibitors of the transcription factor STAT-1 and their medical use. This new patent broadens the protection for the company’s lead development candidate AVT-01 decoy ODN to additional indications not yet covered by the previous patent already granted in the US. AVONTEC’s patents protecting the compound AVT-01 decoy ODN and its medical use in various indications are now granted in the USA, Europe, Australia, China, and Russia and are pending in PCT member states including Japan, Canada and India.

“With the granting of US 7 485 628 our lead compound AVT-01 decoy ODN is now embraced by two independent families of patents in the US providing extended protection. The granting of this patent is an important step in obtaining global patent protection for our most advanced development candidate, and it further strengthens AVONTEC’s leading position in the development of targeted decoy oligonucleotide based therapies.” commented Dr. Thomas Schulze, CEO of AVONTEC.

About AVT-01 decoy ODN

AVT-01 decoy ODN is a double-stranded “decoy” oligonucleotide that effectively inhibits STAT transcription factors (including STAT-1) shown to be strongly involved in the regulation of chronic inflammation. AVT-01 decoy ODN reduced inflammation in numerous pharmacological animal models. In pilot clinical studies this drug candidate showed an excellent safety profile and had demonstrable effects on relevant endpoints.

About chronic inflammation

Chronic inflammation, which includes diseases such as asthma, psoriasis, arthritis, atherosclerosis among others, affects millions of people worldwide. A vast display of complex biological processes is triggered by multiple antigens in an inflammatory environment. In particular the activation of the patient's natural defense mechanisms presents a common underlying of the observed inflammatory complexity. Novel drugs will have to address these fundamental mechanisms. AVT-01 decoy ODN and related oligonucleotides aim at an efficacious and safer treatment enabling the long-term control of the chronic inflammatory disease condition.


AVONTEC is a biopharmaceutical company specialized in the development of novel nucleic acid based therapeutic treatments targeting transcription factors. Transcription factors are the master switches of gene regulation, able to turn genes on and off with exquisite sensitivity. The molecules developed at AVONTEC are designed to specifically attenuate abnormal transcription factor signaling, thereby normalizing the underlying cause of the disease. AVONTEC develops these decoy ODNs as therapeutic agents to treat chronic inflammation. AVONTEC’s lead programs, AVT-01 in asthma and AVT-02 UE in inflammatory skin diseases, have been successfully advanced into Phase IIa clinical trials. In addition, there are several candidates in the pipeline based on AVONTEC’s core decoy technology. AVONTEC operates a lean business model with a seasoned management team experienced in clinical development.



Fraunhoferstraße 15

D-82152 Martinsried

Dr. Thomas Schulze
Phone: +49 (0) 89 8565 - 1600
Fax: +49 (0) 89 8565 - 1620

Press Office


Fraunhoferstraße 15
D-82152 Martinsried
phone: +49 (0)89 8565 1600
fax: +49 (0)89 8565 1620

Publisher Contact Information:

+49 (0) 89 8565 - 1600

Company profile of AVONTEC GmbH
Past press releases of AVONTEC GmbH.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.